World
On the surface, Sun Pharma’s $3.2-billion purchase of Indian generics rival Ranbaxy, which is in deep trouble with US regulators over safety lapses, may...
Hi, what are you looking for?
On the surface, Sun Pharma’s $3.2-billion purchase of Indian generics rival Ranbaxy, which is in deep trouble with US regulators over safety lapses, may...